Therese Kinsella, Professor of Biochemistry at University College Dublin, is a leading expert in the field of prostanoid biology, focusing on the vasculature and has published extensively in this area as the lead author in top peer-reviewed journals As Founder and Chief Executive Officer of ATXA Therapeutics Ltd (ATXA), Therese is the lead inventor on an extensive patent portfolio on the discovery of a novel series of Thromboxane Receptor antagonists currently in early clinical development for treatment of pulmonary arterial hypertension (PAH). ATXA's research has confirmed the benefits of its lead drug candidate NTP42 in preventing or treating PAH in two independent preclinical efficacy models of PAH, including when used as a mono- or dual-therapy with the SOCs. In 2018, ATXA was awarded orphan designation from the EMA (Eu) and from the FDA (USA) for its lead drug NTP42 for PAH. In May '21, ATXA began testing NTP42 in a first-in-human Phase I Clinical Trial in healthy males.